Expression Analysis of a Stress Repressed Gene OsDSR4 from DUF966 Family and Generation of OsDSR4- overexpressing Transgenic Rice(Oryza sativa L. ssp. japonica)

OSdSr4基因是duf966基因家族中的一个未知功能基因,目前其生物学功能尚不清楚。本研究生物信息学分析显示,OSdSr4基因CdnA全长2 167 bP,包含一个1 149 bP的开放阅读框(Orf),编码382个氨基酸,推测的蛋白中包含一个高度保守的duf966结构域;表达模式分析表明,OSdSr4主要在水稻(OryzA SATIVA l.SSP.JAPOnICA)的茎节间和叶片中表达,干旱、高盐和低温等非生物胁迫明显抑制了OSd Sr4的表达,而脱落酸(AbSCISIC ACId,AbA)则显著诱导了它的表达;利用重叠延伸PCr方法成功克隆了OSdSr4,并将其转化进水稻中,获得了32株超表达转基因植株。分子鉴定结果表明,该基因已被整合进水稻基因组中,并在部分转基因植株中实现了超量表达。本实验为进一步开展OSdSr4基因的生物学功能研究提供了基础资料。OsDSR4 is a gene of unkown function in DUF966 gene family,and the function of DUF966 family genes have not been reported until now.In this study,the bioinformatic analysis showed that the cDNA of OsDSR4 had 2 167 bp containing an open reading frame(ORF) of 1 149 bp,and it encoded a putative protein of 372 amino acids with a highly conserved DUF966 domain.The gene expression profile analysis indicated that OsDSR4 was expressed mainly in internode and leaf blade of rice(Oryza sativa L.),and it was repressed markedly by drought,salt and cold stresses,and induced significantly by abscisic acid(ABA).OsDSR4 was cloned using overlap extension PCR,and the fusion construct containing OsDSR4 was introduced into rice(Oryza sativa L.ssp.japonica) by Agrobacterium- mediated transformation method.Thirty- two OsDSR4- overexpressing transgenic plants were obtained and identified by PCR and qRT-PCR,which was demonstated that OsDSR4 had been integrated into rice genome and was overexpressed in some positive transgenic plants.These results establish the foundation for further study of the precise function of OsDSR4.国家重点基础研究发展计划(973)前期研究专项(No.2012CB126312

用于待测物拉曼光谱检测的复合粒子、其制备方法及使用方法

本发明提供了一种用于待测物拉曼光谱检测的复合粒子。该复合粒子由磁性粒子和金属核壳纳米粒子组成，该金属核壳纳米粒子附着在该磁性粒子表面，并且该金属核壳纳米粒子具有惰性外壳。该复合粒子具有高SERS活性、能够用于溶液中进行原位拉曼检测，并且能够重复使用，因此在物质拉曼光谱检测中具有良好的应用价值，能够有效拓宽表面增强拉曼光谱技术的应用范围

一种电场调控下显色材料及其制备方法

本发明公开了一种电场调控下显色材料，包括介质与均匀分散在所述介质中的胶体晶体材料，所述介质为碳酸丙烯酯或水;所述胶体晶体材料为氧化钛包覆的氧化硅胶态纳米粒子SiO2/TiO2;所述胶体晶体材料与介质的体积比为（1～8）:（90～95）。本发明制得的显色材料是一种新的电场调控可变色材料，增加了电场调控显色材料的种类，通过一步法合成SiO2/TiO2胶体纳米粒子，方法简单有效，通过调控钛源的加入量可以实现不同厚度的氧化钛的包覆;制得的显色材料显示的颜色亮度高，在很小的电场作用下就具有明显的颜色变化，且响应速度快

镜面起伏对1.55 μm Si基MEMS光滤波器的影响

用传输矩阵方法，在简化的光学模型基础上，分别讨论了分布式Bragg反射镜DBR（Distributed Bragg Reflector）的生长精度及镜面起伏对1.55 μm Si基MEMS（Micro-Electro-Mechanical-System）可调谐光滤波器透射谱的影响。计算表

新疆干旱区典型荒漠生态系统综合整治技术研发与示范

一、项目简要说明 本研究以塔里木河下游为主要研究对象,开展“新疆干旱区典型荒漠生态系统综合整治技术模式”研究,课题目标和研究任务密切结合国家西部大开发塔里木河流域生态整治工程需求,研究成果对加快塔里木河流域生态整治,促进区域生态安全和社会经济可持续发展具有重要意义。本研究对项目区开展了全面的野外调查、资料采集、分析化验、以及技术研发与试验示范等工作,定期对土壤水分、土壤盐分、地下水位、地下水质、植物生理生化指标、土壤呼吸等进行了监测,采集样品及数据达24000余组(份);分析了不同干旱胁迫下荒漠河岸林植物的耗水特性与耗水机理,提出了荒漠河岸林的生态阈值,发现了荒漠植物自适应机理和避害机制..

Aripiprazole versus other atypical antipsychotics for schizophrenia

BACKGROUND: In most western industrialised countries, second generation (atypical) antipsychotics are recommended as first line drug treatments for people with schizophrenia. In this review we specifically examine how the efficacy and tolerability of one such agent - aripiprazole - differs from that of other comparable second generation antipsychotics. OBJECTIVES: To evaluate the effects of aripiprazole compared with other atypical antipsychotics for people with schizophrenia and schizophrenia-like psychoses. SEARCH METHODS: We searched the Cochrane Schizophrenia Group Trials Register (November 2011), inspected references of all identified studies for further trials, and contacted relevant pharmaceutical companies, drug approval agencies and authors of trials for additional information. SELECTION CRITERIA: We included all randomised clinical trials (RCTs) comparing aripiprazole (oral) with oral and parenteral forms of amisulpride, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone or zotepine for people with schizophrenia or schizophrenia-like psychoses. DATA COLLECTION AND ANALYSIS: We extracted data independently. For dichotomous data we calculated risk ratios (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis based on a random-effects model. Where possible, we calculated illustrative comparative risks for primary outcomes. For continuous data, we calculated mean differences (MD), again based on a random-effects model. We assessed risk of bias for each included study. MAIN RESULTS: We included 12 trials involving 6389 patients. Aripiprazole was compared to olanzapine, risperidone and ziprasidone. All trials were sponsored by an interested drug manufacturer. The overall number of participants leaving studies early was 30% to 40%, limiting validity (no differences between groups).When compared with olanzapine no differences were apparent for global state (no clinically important change: n = 703, 1 RCT, RR short-term 1.00 95% CI 0.81 to 1.22; n = 317, 1 RCT, RR medium-term 1.08 95% CI 0.95 to 1.22) but mental state tended to favour olanzapine (n = 1360, 3 RCTs, MD total Positive and Negative Syndrome Scale (PANSS) 4.68 95% CI 2.21 to 7.16). There was no significant difference in extrapyramidal symptoms (n = 529, 2 RCTs, RR 0.99 95% CI 0.62 to 1.59) but fewer in the aripiprazole group had increased cholesterol levels (n = 223, 1 RCT, RR 0.32 95% CI 0.19 to 0.54) or weight gain of 7% or more of total body weight (n = 1095, 3 RCTs, RR 0.39 95% CI 0.28 to 0.54).When compared with risperidone, aripiprazole showed no advantage in terms of global state (n = 384, 2 RCTs, RR no important improvement 1.14 95% CI 0.81 to 1.60) or mental state (n = 372, 2 RCTs, MD total PANSS 1.50 95% CI -2.96 to 5.96).One study compared aripiprazole with ziprasidone (n = 247) and both the groups reported similar change in the global state (n = 247, 1 RCT, MD average change in Clinical Global Impression-Severity (CGI-S) score -0.03 95% CI -0.28 to 0.22) and mental state (n = 247, 1 RCT, MD change PANSS -3.00 95% CI -7.29 to 1.29).When compared with any one of several new generation antipsychotic drugs the aripiprazole group showed improvement in global state in energy (n = 523, 1 RCT, RR 0.69 95% CI 0.56 to 0.84), mood (n = 523, 1 RCT, RR 0.77 95% CI 0.65 to 0.92), negative symptoms (n = 523, 1 RCT, RR 0.82 95% CI 0.68 to 0.99), somnolence (n = 523, 1 RCT, RR 0.80 95% CI 0.69 to 0.93) and weight gain (n = 523, 1 RCT, RR 0.84 95% CI 0.76 to 0.94). Significantly more people given aripiprazole reported symptoms of nausea (n = 2881, 3 RCTs, RR 3.13 95% CI 2.12 to 4.61) but weight gain (7% or more of total body weight) was less common in people allocated aripiprazole (n = 330, 1 RCT, RR 0.35 95% CI 0.19 to 0.64). Aripiprazole may have value in aggression but data are limited. This will be the focus of another review. AUTHORS' CONCLUSIONS: Information on all comparisons are of limited quality, are incomplete and problematic to apply clinically. Aripiprazole is an antipsychotic drug with a variant but not absent adverse effect profile. Long-term data are sparse and there is considerable scope for another update of this review as new data emerges from the many Chinese studies as well as from ongoing larger, independent pragmatic trials

Measurement of integrated luminosity of data collected at 3.773 GeV by BESIII from 2021 to 2024

We present a measurement of the integrated luminosity e+e- of collision data collected by the BESIII detector at the BEPCII collider at a center-of-mass energy of Ecm = 3.773 GeV. The integrated luminosities of the datasets taken from December 2021 to June 2022, from November 2022 to June 2023, and from October 2023 to February 2024 were determined to be 4.995±0.019 fb-1, 8.157±0.031 fb-1, and 4.191±0.016 fb-1, respectively, by analyzing large angle Bhabha scattering events. The uncertainties are dominated by systematic effects, and the statistical uncertainties are negligible. Our results provide essential input for future analyses and precision measurements

Determination of the number of ψ(3686) events taken at BESIII

The number of ψ(3686) events collected by the BESIII detector during the 2021 run period is determined to be (2259.3±11.1)×106 by counting inclusive ψ(3686) hadronic events. The uncertainty is systematic and the statistical uncertainty is negligible. Meanwhile, the numbers of ψ(3686) events collected during the 2009 and 2012 run periods are updated to be (107.7±0.6)×106 and (345.4±2.6)×106, respectively. Both numbers are consistent with the previous measurements within one standard deviation. The total number of ψ(3686) events in the three data samples is (2712.4±14.3)×10^